Review of biologics in allergic contact dermatitis
Abstract
The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes its management challenging. With advances in the understanding of the cellular and molecular pathogenesis of ACD, newer therapeutic targets are becoming apparent. In particular, the use of biologics has gained momentum, given the specificity of their action. This article aims to review the presently available data on the use of biologics in ACD. English-language-based literature available on the use of biological therapy was thoroughly probed in the following databases as on October 14, 2019: PubMed, Google Scholar, The Cochrane library, Embase, Scopus, and EBSCO. The following keywords were used: "contact dermatitis", "allergens", "delayed-type hypersensitivity reaction", "biologics", "biological therapy", "monoclonal antibodies", "patch testing", "TNF-α inhibitors", "infliximab", "adalimumab", "etanercept", "dupilumab", "omalizumab", "secukinumab", "ustekinumab", "rituximab".
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Unlike some systemic therapies for ACD, dupilumab benefits from its lack of notable immunosuppressive effects.
“Unlike some systemic therapies for ACD, dupilumab also benefits from its lack of notable immunosuppressive effects.9”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [9]
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
Johnson, H. (2022) · Current Psychiatry · doi:10.12788/cutis.0519 · Cited by 20 · see citing works
- Authors
- Bhatia, J., Sarin, A., Wollina, U., Lotti, T., Navarini, A. A., Mueller, S. M., Grabbe, S., Saloga, J., Rokni, G. R., & Goldust, M.
- Affiliations
- Department of Dermatology Sarin Skin Solutions New Delhi India
- Städtisches Klinikum Dresden (DE)
- Marconi University (IT)
- University Hospital of Basel (CH)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Mazandaran University of Medical Sciences (IR)
- Corresponding author
- Goldust, Mohamad
- ORCID
- Venue
- Contact Dermatitis
- Publisher
- Wiley
- Published
- 2020-06-17
- Volume
- 83
- Issue
- 3
- Pages
- 179-181
- ISSN
- 0105-1873 (ISSN-L)
- 1600-0536
- OpenAlex
- W3020701782
- Cited by
- 25
- References
- 1
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 5
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Contact Dermatitis (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Keywords
- allergic contact dermatitis, biologics, biologic therapy, monoclonal antibodies, TNF-alpha inhibitors, dupilumab, omalizumab, secukinumab, ustekinumab, rituximab, infliximab, adalimumab, etanercept, delayed-type hypersensitivity, pathogenesis
- MeSH terms
- Biological Products, Humans, Patch Tests, Treatment Outcome, Dermatitis, Allergic Contact
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
